We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.33%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$294M
AUM Growth
+$106M
Cap. Flow
+$106M
Cap. Flow %
35.98%
Top 10 Hldgs %
58.58%
Holding
91
New
29
Increased
26
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$27.6M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$7.56M
3
TVTX icon
Travere Therapeutics
TVTX
+$6.08M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.85M
5
NAUT icon
Nautilus Biotechnolgy
NAUT
+$5.39M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$29.6M
2
CRIS icon
Curis
CRIS
+$4.71M
3
STRO icon
Sutro Biopharma
STRO
+$2.85M
4
ATNX
Athenex, Inc. Common Stock
ATNX
+$2.21M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 63.48%
2 Financials 2.49%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFIB
51
DELISTED
Acutus Medical Inc
AFIB
$802K 0.27%
+60,000
New +$1.35M
MGNX icon
52
MacroGenics
MGNX
$278M
$796K 0.27%
+25,000
New +$607K
CHAQ.U
53
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$789K 0.27%
+75,000
New +$853K
IOVA icon
54
Iovance Biotherapeutics
IOVA
$2.24B
$779K 0.26%
24,600
+5,000
+26% +$207K
CCCC icon
55
C4 Therapeutics
CCCC
$390M
$740K 0.25%
20,000
– –
ASLN
56
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$670K 0.23%
+5,000
New +$634K
MRNA icon
57
CALL
Moderna
MRNA
$24.4B
$655K 0.22%
+5,000
New +$725K
XFOR icon
58
X4 Pharmaceuticals
XFOR
$344M
$646K 0.22%
+2,500
New +$657K
ESTA icon
59
Establishment Labs
ESTA
$2.77B
$625K 0.21%
+10,000
New +$577K
PCVX icon
60
Vaxcyte
PCVX
$8.02B
$593K 0.2%
30,000
– –
IMTXW
61
DELISTED
Immatics N.V. Warrants
IMTXW
$590K 0.2%
200,000
-42,855
-18% -$128K
AXSM icon
62
Axsome Therapeutics
AXSM
$11.7B
$566K 0.19%
10,000
– –
BYSI icon
63
BeyondSpring
BYSI
$51.8M
$554K 0.19%
50,000
-25,000
-33% -$323K
EPZM
64
DELISTED
Epizyme, Inc
EPZM
$436K 0.15%
+50,000
New +$517K
HARP
65
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$418K 0.14%
+2,000
New +$401K
ACHL
66
DELISTED
Achilles Therapeutics
ACHL
$414K 0.14%
+25,000
New +$414K
CTMX icon
67
CytomX Therapeutics
CTMX
$773M
$387K 0.13%
+50,000
New +$396K
CEREW
68
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$312K 0.11%
72,466
– –
WINT
69
DELISTED
Windtree Therapeutics
WINT
$105K 0.04%
+1
New +$216K
SKINW
70
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
$94K 0.03%
45,000
+11,667
+35% +$28.6K
ZYNE
71
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$62K 0.02%
13,285
– –
AXSM icon
72
CALL
Axsome Therapeutics
AXSM
$11.7B
– –
-25,000
Closed -$2.04M
CRSP icon
73
CRISPR Therapeutics
CRSP
$4.68B
– –
-3,500
Closed -$536K
IMVT icon
74
Immunovant
IMVT
$8.23B
– –
-75,000
Closed -$1.98M
CYPH
75
Cypherpunk Technologies Inc
CYPH
$77.5M
– –
-90,460
Closed -$2.04M
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Affinity Asset Advisors held 91 positions worth $294M, up 56% from $189M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Affinity Asset Advisors deployed $106M of net new capital in Q1 2021, opening 29 new positions and adding to 26 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp IV Class A Odinary Shares: 700,000 shares worth $7.33M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Curis, an estimated $4.71M trimmed.

  • Affinity Asset Advisors's largest Q1 2021 buy was ARYA Sciences Acquisition Corp IV Class A Odinary Shares: 700,000 shares worth $7.33M.
  • Affinity Asset Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $27.6M increase.
  • Affinity Asset Advisors's biggest Q1 2021 reduction was Curis, cutting an estimated $4.71M.
  • Affinity Asset Advisors fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $29.6M.
  • Affinity Asset Advisors's ten largest holdings make up 59% of its $294M portfolio in Q1 2021.
  • Affinity Asset Advisors opened 29 new positions and closed 19 in Q1 2021.
  • Affinity Asset Advisors's portfolio value rose 56% quarter-over-quarter to $294M.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.